Last reviewed · How we verify
NCT03211130
Using SystemCHANGE™ to Enhance Medication Adherence in Older Adult Stroke Survivors
EARLY_PHASE1 trial testing SystemCHANGE™ in Stroke, Ischemic in 30 participants. Completed in 24 May 2018.
6 February 2018
Quick facts
| Lead sponsor | University of Missouri, Kansas City |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 30 |
| Start date | 28 November 2017 |
| Primary completion | 6 February 2018 |
| Estimated completion | 24 May 2018 |
| Sites | 1 location across United States |
Drugs / interventions tested
- SystemCHANGE™
- Attention-Control
Conditions studied
- Stroke, Ischemic — all drugs for Stroke, Ischemic →
Sponsor
University of Missouri, Kansas City
Who can join
50 and older, any sex, with Stroke, Ischemic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study evaluated the feasibility and acceptability of using a SystemCHANGE intervention in older adult stroke survivors to improve medication adherence. Half the participants will receive the SystemCHANGE intervention, while the other half will receive the attention-control education intervention.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03211130
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Stroke, Ischemic
Currently open trials in the same condition.
- NCT07456956 — HIIT vs MCIT for Stroke-Related Sarcopenia in Ischemic Stroke · NA · recruiting
- NCT06658197 — Efficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke · Phase 3 · recruiting
- NCT07282041 — Role of GLP1 RA Dulaglutide on Severe Intracranial Atherosclerosis · Phase 2, PHASE3 · recruiting
- NCT07135089 — Improving Neuroprotective Strategy for Ischemic Stroke Before Endovascular Thrombectomy by Intravenous Tirofiban · Phase 3 · recruiting
- NCT07047014 — Advancing Reperfusion Therapy for Ischemic Stroke (ARTS): Tenecteplase in Medium Vessel Occlusion (MeVO) for Acute Ische · Phase 3 · recruiting
Other University of Missouri, Kansas City trials
Trials by the same sponsor.
- NCT06517628 — The Heart Outcomes in Pregnancy Expectations for Mom and Baby Study · recruiting
- NCT04556227 — Simultaneous Recumbent Cycling and Cognitive Training · NA · recruiting
- NCT07450209 — COVID-19 Rapid Test-to-Treat With African American Churches (Faithful Response II) · Phase 2 · active not recruiting
- NCT06374186 — Continuous Glucose Monitoring, Contingency Management, and Motivational Interviewing for Patients With Type 2 Diabetes i · NA · completed
- NCT06133959 — Healthy ME: Advancing Health Equity in Lymphatic Pain and Lymphedema in Black and Hispanic Women With Breast Cancer · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03211130 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Missouri, Kansas City
- Last refreshed: 21 August 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03211130.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing